News

Iconovo has recently made the strategic decision to invest heavily in developing a new inhalation platform – ICOpre.

With this investment, the company hopes to be able to offer generic versions of GSK’s Ellipta portfolio, which is expected to have a market value of 5 BUSD by 2024. BioStock takes a closer look at the stakes involved for Iconovo in making this big bet. Read more